190 related articles for article (PubMed ID: 18026991)
1. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine.
Pu XY; Wang ZP; Chen YR; Wang XH; Wu YL; Wang HP
J Cancer Res Clin Oncol; 2008 Jun; 134(6):659-65. PubMed ID: 18026991
[TBL] [Abstract][Full Text] [Related]
2. Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor.
Retz M; Lehmann J; Amann E; Wullich B; Röder C; Stöckle M
J Urol; 2003 Jan; 169(1):86-9. PubMed ID: 12478110
[TBL] [Abstract][Full Text] [Related]
3. The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine.
Eissa S; Badr S; Elhamid SA; Helmy AS; Nour M; Esmat M
Dis Markers; 2013; 34(1):57-62. PubMed ID: 22960341
[TBL] [Abstract][Full Text] [Related]
4. Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor.
Okegawa T; Kinjo M; Horie S; Nutahara K; Higashihara E
Urology; 2003 Jul; 62(1):182-6. PubMed ID: 12837463
[TBL] [Abstract][Full Text] [Related]
5. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.
Eissa S; Zohny SF; Swellam M; Mahmoud MH; El-Zayat TM; Salem AM
Clin Biochem; 2008 Nov; 41(16-17):1335-41. PubMed ID: 18804101
[TBL] [Abstract][Full Text] [Related]
6. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin.
Kenney DM; Geschwindt RD; Kary MR; Linic JM; Sardesai NY; Li ZQ
Tumour Biol; 2007; 28(2):57-62. PubMed ID: 17259754
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic efficacy of urinary survivin and hyaluronidase mRNA as urine markers in patients with bladder cancer.
Eissa S; Badr S; Barakat M; Zaghloul AS; Mohanad M
Clin Lab; 2013; 59(7-8):893-900. PubMed ID: 24133921
[TBL] [Abstract][Full Text] [Related]
8. Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas.
Pina-Cabral L; Santos L; Mesquita B; Amaro T; Magalhães S; Criado B
Clin Transl Oncol; 2007 Nov; 9(11):731-6. PubMed ID: 18055328
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic value of bladder cancer-related transcript markers in urine.
Schmidt J; Propping C; Siow WY; Lohse-Fischer A; Toma M; Baldauf-Twelker A; Hakenberg OW; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Feb; 142(2):401-14. PubMed ID: 26328914
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis.
Weikert S; Christoph F; Schrader M; Krause H; Miller K; Müller M
Int J Cancer; 2005 Aug; 116(1):100-4. PubMed ID: 15761870
[TBL] [Abstract][Full Text] [Related]
11. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.
Shariat SF; Casella R; Khoddami SM; Hernandez G; Sulser T; Gasser TC; Lerner SP
J Urol; 2004 Feb; 171(2 Pt 1):626-30. PubMed ID: 14713774
[TBL] [Abstract][Full Text] [Related]
12. The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors.
Smrkolj T; Cegovnik Primozic U; Fabjan T; Sterpin S; Osredkar J
Radiol Oncol; 2020 Dec; 55(2):196-202. PubMed ID: 33764701
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer.
Moussa O; Abol-Enein H; Bissada NK; Keane T; Ghoneim MA; Watson DK
J Urol; 2006 Jun; 175(6):2312-6. PubMed ID: 16697865
[TBL] [Abstract][Full Text] [Related]
15. [Value of combined detection of urinary Livin and Survivin mRNA expression in the early diagnosis of bladder cancer].
Jiang LL; Xie MM; Wang XR; Zhao Y; Wang ZJ
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3520-2. PubMed ID: 24521893
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
17. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
Ganas V; Kalaitzis C; Sountoulides P; Giannakopoulos S; Touloupidis S
Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
[TBL] [Abstract][Full Text] [Related]
18. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.
Eissa S; Swellam M; Shehata H; El-Khouly IM; El-Zayat T; El-Ahmady O
J Urol; 2010 Feb; 183(2):493-8. PubMed ID: 20006858
[TBL] [Abstract][Full Text] [Related]
19. Urine detection of survivin and diagnosis of bladder cancer.
Smith SD; Wheeler MA; Plescia J; Colberg JW; Weiss RM; Altieri DC
JAMA; 2001 Jan; 285(3):324-8. PubMed ID: 11176843
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer.
Shabayek MI; Sayed OM; Attaia HA; Awida HA; Abozeed H
Pathol Oncol Res; 2014 Oct; 20(4):859-66. PubMed ID: 24696417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
